natgillin/translations-raw huggingface dataset:
It will also provide doctors and patients using the medicine for GPA, MPA or pemphigus with educational material on the risk of infection including that of a rare severe infection, progressive multifocal leukoencephalopathy (PML). 
Turustaja annab arstidele ja patsientidele, kes kasutavad ravimit granulomatoosse polüangiidi, mikroskoopilise polüangiidi või hariliku villtõve raviks, ka teabematerjali infektsiooniriski, sealhulgas raske harvikinfektsiooni progresseeruva multifokaalse leukoentsefalopaatia riski kohta.
The reference medicine for Riximyo is MabThera. 
Riximyo võrdlusravim on MabThera.
In addition, Riximyo was as effective as MabThera in one main study involving 629 patients with advanced, untreated follicular lymphoma, where Riximyo or MabThera were added to other chemotherapy for part of the treatment. 
Riximyo ja MabThera võrreldavat efektiivsust tõendati ka ühes põhiuuringus, kus osales 629 varem ravimata kaugelearenenud follikulaarlümfoomiga patsienti ning milles muule keemiaravile lisati teatavaks ajaks Riximyo või MabThera.
Because Riximyo is a biosimilar medicine, the studies on effectiveness and safety of rituximab carried out with MabThera do not all need to be repeated for Riximyo. 
Et Riximyo on bioloogiliselt sarnane ravim, ei pea MabTheraga tehtud rituksimabi efektiivsus- ja ohutusuuringuid Riximyoga kordama.
Studies have also shown that giving Riximyo produces similar levels of the active substance in the body to giving MabThera. 
Uuringud on samuti näidanud, et Riximyo põhjustab organismis samasuguse toimeainesisalduse kui MabThera.
Patients with GPA, MPA or pemphigus vulgaris must also not receive Riximyo if they have severe heart problems. 
Granulomatoosse polüangiidi, mikroskoopilise polüangiidi või hariliku villtõvega patsiendid ei tohi kasutada Riximyot raskete südameprobleemide korral.
The active substance in Riximyo, rituximab, is a monoclonal antibody designed to attach to a protein called CD20, which is present on B cells. 
Riximyo toimeaine rituksimab on monoklonaalne antikeha, mis seondub B-lümfotsüütide pinnal oleva valguga CD20.
When rituximab attaches to CD20, it causes the B cells to die, which helps in lymphoma and CLL (where B cells have become cancerous) and in pemphigus (where B cells are involved in inflammation). 
Rituksimabi seondumisel valguga CD20 B-lümfotsüüdid hävivad, mis aitab ravida lümfoomi ja kroonilist lümfotsüütleukeemiat (B-lümfotsüüdid on muutunud pahaloomuliseks) ning villtõbe (B-lümfotsüüdid osalevad põletikuprotsessis).
Laboratory studies comparing Riximyo with the reference medicine MabThera have shown that the active substance in Riximyo is highly similar to that in MabThera in terms of structure, purity and biological activity. 
Riximyot võrreldi võrdlusravimi MabTheraga laboriuuringutes, mis tõendasid, et Riximyo toimeaine on struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane MabThera toimeainega.
Riximyo contains the active substance rituximab. 
Riximyo sisaldab toimeainena rituksimabi.
An overview of Riximyo and why it is authorised in the EU 
Ülevaade ravimist Riximyo ja ELis müügiloa väljastamise põhjendus
In addition, a study in patients with follicular lymphoma has shown that the safety and effectiveness of Riximyo are equivalent to those of MabThera. 
Peale selle näitas follikulaarlümfoomiga patsientide uuring nende ravimite võrreldavat ohutust ja efektiivsust.
What benefits of Riximyo have been shown in studies? 
Milles seisneb uuringute põhjal Riximyo kasulikkus?
All these data were considered sufficient to conclude that Riximyo will behave in the same way as MabThera in terms of effectiveness and safety in its authorised uses. 
Nende piisavate andmete põhjal järeldati, et Riximyo efektiivsus ja ohutus on heakskiidetud näidustustel võrreldavad MabThera efektiivsuse ja ohutusega.
How is Riximyo used? 
Kuidas Riximyot kasutatakse?
For the full list of side effects and restrictions of Riximyo, see the package leaflet. 
Riximyo kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
Riximyo is a ‘biosimilar medicine'. 
Riximyo on bioloogiliselt sarnane ravim.
Riximyo can only be obtained with a prescription. 
Riximyo on retseptiravim.
The full EPAR and risk management plan summary for Episalvan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Episalvani kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A risk management plan has been developed to ensure that Episalvan is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada Episalvani võimalikult ohutu kasutamine.
What measures are being taken to ensure the safe and effective use of Episalvan? 
Mis meetmed võetakse, et tagada Episalvani ohutu ja efektiivne kasutamine?
With regard to safety, no major issues were identified and side effects were manageable. 
Mis puutub ohutusse, siis olulisi probleeme ei tuvastatud ja kõrvaltoimed olid kergesti käsitletavad.
Other information about Episalvan 
Muu teave Episalvani kohta
The exact way Episalvan works is not fully understood. 
Episalvani täpne toimemehhanism ei ole täielikult teada.
The respective times were 16.0 and 15.1 days respectively in the second study. 
Teises uuringus olid vastavad ajad 16,0 ja 15,1 päeva.
What is Episalvan and what is it used for? 
Mis on Episalvan ja milleks seda kasutatakse?
Although the differences were small they were considered relevant for patients with partial-thickness wounds, which can be difficult to heal and for which treatment options are limited. 
Kuigi erinevused on väikesed, on need väärtuslikud patsientidele, kellel on pindmised haavad, mille ravimine võib olla keeruline ja ravivõimalused piiratud.
The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Episalvan's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Inimravimite komitee otsustas, et Episalvani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
This is a summary of the European public assessment report (EPAR) for Episalvan. 
See on ravimi Episalvan Euroopa avaliku hindamisaruande kokkuvõte.
Why is Episalvan approved? 
Miks Episalvan heaks kiideti?
The gel should be re-applied with every dressing change, until the wound is healed, for up to 4 weeks. 
Geeli tuleb kuni 4 nädala jooksul igal sideme vahetamisel uuesti haavale kanda, kuni haav paraneb.
The most common side effects with Episalvan are wound complications, pain in the skin (both of which may affect more than 3 in 100 people) and pruritus (itching) (which may affect more 1 in 100 people). 
Episalvani kõige sagedamad kõrvalnähud on haava tüsistused, valu nahas (võivad esineda enam kui 3 patsiendil 100st) ja pruritus (sügelus) (võib esineda enam kui 1 patsiendil 100st).
The average time to wound closure was 8.8 days for the wounds treated with standard disinfectant gel and 7.6 days for the wounds treated with Episalvan. 
Keskmine aeg haava sulgumiseni oli 8,8 päeva haava ravimisel tavapärase desinfitseeriva geeliga ja 7,6 päeva haava ravimisel Episalvaniga.
For the full list of all side effects and restrictions reported with Episalvan, see the package leaflet. 
Episalvani kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Episalvan, including the appropriate precautions to be followed by healthcare professionals and patients. 
Selle alusel lisati Episalvani omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
What are the risks associated with Episalvan? 
Mis riskid Episalvaniga kaasnevad?
It is not intended to provide practical advice on how to use Episalvan. 
Hindamisaruandes ei anta Episalvani kasutamise praktilisi nõuandeid.
Episalvan was studied in two main studies involving 217 patients with partial-thickness skin wounds in patients who underwent skin graft surgery. 
Episalvanit uuriti kahes põhiuuringus 217-l pindmiste nahahaavadega patsiendil, kellele siirati nahka.
Episalvan gel was shown to reduce wound healing times. 
Episalvan geel lühendab haava paranemise kestust.
For practical information about using Episalvan, patients should read the package leaflet or contact their doctor or pharmacist. 
Kui vajate Episalvani kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
It is thought that the active substance in Episalvan, birch bark extract, helps the cells that make up the outer layer of the skin (keratinocytes) grow and move quickly towards the gap created by the wound, therefore helping wounds to heal faster. 
Arvatakse, et Episalvani toimeaine kasetohuekstrakt aitab naha välimist kihti moodustavatel rakkudel (keratinotsüüdid) kasvada ja kiiresti haavakanali suunas migreeruda, võimaldades haavadel kiiremini paraneda.
In the first study, the average time from surgery to wound closure was 17.1 days for the wounds treated with standard wound dressing only and 15.5 days for the wounds also treated with Episalvan. 
Esimese uuringu põhjal oli keskmine aeg kirurgilisest sekkumisest kuni haava sulgumiseni 17,1 päeva, kui kasutati vaid tavapärast haavasidumist, ja 15,5 päeva, kui haavale kanti lisaks ka Episalvanit.
These are wounds where the upper layers of the skin have been lost, for example by a burn or during surgical skin grafting. 
Pindmiste haavade korral on hävinud naha pealmised kihid, näiteks põletuse või kirurgilise nahatransplantaadi võtmise korral.
Episalvan is a medicine used in adults to treat partial-thickness skin wounds. 
Episalvanit kasutatakse pindmiste nahahaavade ravimiseks täiskasvanutel.
For more information about treatment with Episalvan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Episalvaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
A third study involved 57 patients with partial-thickness burn wounds who had half their wound treated with Episalvan and the other half with a standard disinfectant gel. 
Kolmandas uuringus, milles osales 57 pindmiste põletushaavadega patsienti, raviti haava ühte poolt Episalvaniga ja teist tavapärase desinfitseeriva geeliga.
How is Episalvan used? 
Kuidas Episalvanit kasutatakse?
Both wound halves were also covered with a wound dressing. 
Haava mõlemale poolele asetati ka side.
Episalvan is available as a gel that should be applied as a thin layer (1 mm in thickness) to the wound, which should then be covered by a wound dressing. 
Episalvanit turustatakse geelina, mida tuleb kanda õhukese kihina (paksus 1 mm) haavale ja haava seejärel siduda.
How does Episalvan work? 
Kuidas Episalvan toimib?
What benefits of Episalvan have been shown in studies? 
Milles seisneb uuringute põhjal Episalvani kasulikkus?
The patients received Episalvan together with wound dressing on one half of the wound, while the other half of the wound was treated with standard wound dressing only. 
Patsientide haava ühele poolele asetati side koos Episalvaniga ja haava teisele poolele asetati ainult side.
Episalvan contains a dry extract from birch bark. 
Episalvan sisaldab kasetohust tehtud kuivekstrakti.
Episalvan birch bark extract 
Episalvan kasetohuekstrakt
What is Fulphila? 
Mis on Fulphila?
Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim) EMA/577551/2017 
Müügiloa taotluse tagasivõtmise teave: Fulphila (pegfilgrastiim) EMA/577551/2017
Other concerns related to the description of the manufacturing process, the control of impurities in the active substance and the sterilisation of the final product. 
Muud probleemid olid seotud tootmisprotsessi kirjelduse, toimeaine lisandisisalduse reguleerimise ja lõpptoote steriliseerimisega.
Neutropenia is a side effect of certain cancer treatments and can lead to development of serious infections. 
Neutropeenia on teatud vähiravimite kõrvalnäht ning võib põhjustada raskeid infektsioone.
Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim) 
Müügiloa taotluse tagasivõtmise teave: Fulphila (pegfilgrastiim)
Fulphila is a medicine that contains the active substance pegfilgrastim. 
Fulphila on ravim, mis sisaldab toimeainena pegfilgrastiimi.
The company presented results of studies designed to show that Fulphila is highly similar to its reference medicine Neulasta in terms of chemical structure, purity, the way it works and how the body handles the medicine. 
Ettevõte esitas tulemused uuringutest, mille eesmärk oli tõendada, et Fulphila sarnaneb keemilise struktuuri, puhtuse, toimemehhanismi ja organismis metaboliseerumise poolest võrdlusravimiga Neulasta.
This means that Fulphila was intended to be highly similar to a biological medicine already authorised in the European Union (the ‘reference medicine') called Neulasta. 
See tähendab, et Fulphila pidi olema sarnane bioloogilise ravimiga (võrdlusravimiga) Neulasta, millel juba on Euroopa Liidus müügiluba.
It encourages the bone marrow to produce more neutrophils and improves the patient's ability to fight off infections. 
See soodustab neutrofiilide teket luuüdis ja suurendab patsiendi vastupanuvõimet infektsioonidele.
Because filgrastim is pegylated, its removal from the body is slowed down, allowing the medicine to be given less often. 
Et filgrastiim on pegüleeritud, püsib see organismis kauem ja ravimit saab manustada harvem.
One of the CHMP's main concerns was the lack of a certificate of Good Manufacturing Practice (GMP) for the manufacturing site of the product. 
Üks komitee väljendatud põhiprobleeme oli, et ravimi tootmiskohal puudus hea tootmistava sertifikaat.
Fulphila was to be used in cancer patients to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and the occurrence of febrile neutropenia (neutropenia with fever). 
Fulphilat kavatseti kasutada vähipatsientidel, et vähendada neutropeenia kestust (neutropeenia on neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus) ja febriilse (palavikuga) neutropeenia esinemissagedust.
In addition, one study in 194 patients receiving cancer medicines compared the safety, effectiveness and immunogenicity, meaning the medicine's ability to trigger the production of antibodies, of Fulphila and Neulasta. 
Peale selle võrreldi ühes 194 vähiravipatsiendi uuringus Fulphila ja Neulasta ohutust, efektiivsust ja immunogeensust (ravimi võimet stimuleerida antikehade teket).
In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing the application because a GMP certificate for the manufacturing site of Fulphila could not be obtained in the time available. 
Ettevõtte kirjas, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et võtab taotluse tagasi, sest ta ei suutnud ettenähtud aja jooksul hankida Fulphila tootmiskoha jaoks hea tootmistava sertifikaati.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the quality of Fulphila had not been demonstrated. 
Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ravimi Fulphila kvaliteet ei ole tõendatud.
Fulphila was developed as a ‘biosimilar' medicine. 
Fulphila töötati välja bioloogiliselt sarnase ravimina.
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Fulphila could not have been approved to reduce neutropenia in patients taking cancer treatments. 
Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Fulphila kasutamist neutropeenia vähendamiseks vähiravi saavatel patsientidel ei ole võimalik heaks kiita.
The company informed the CHMP that the withdrawal does not impact ongoing clinical trials with Fulphila. 
Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Fulphila kliinilistes uuringutes osalevaid patsiente.
The active substance in Fulphila and Neulasta, pegfilgrastim, consists of filgrastim that has been 'pegylated' (attached to a chemical called polyethylene glycol). 
Fulphila ja Neulasta toimeaine pegfilgrastiim koosneb pegüleeritud (polüetüleenglükooliga (PEG) kaetud) filgrastiimist.
protein called granulocyte-colony-stimulating factor (G-CSF). 
Filgrastiim on väga sarnane teatud inimvalguga, granülotsüütide kolooniat stimuleeriva faktoriga (G-CSF).
What was Fulphila expected to be used for? 
Milleks kavatseti Fulphilat kasutada?
officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Fulphila, for reducing neutropenia in patients taking cancer treatments. 
teatas 3. augustil 2017 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Fulphila müügiloa taotlus.
1 vial +1 infusion bag +1 syringe +1 vial adaptor 
1 viaal + infusioonikott + 1 süstal + 1 viaali adapter
Powder : 200mg Solvent: 20 ml (10 mg/ml) 
Pulber: 200 mg Lahusti: 20 ml (10 mg/ml)
Intravenous use Powder: vial (glass) Solvent: infusion bag 
Pulber: klaasviaal Lahusti: infusioonikott
Powder for solution for infusion 
200 mg Infusioonilahuse pulber
Powder and solvent for solution for infusion 
200 mg Infusioonilahuse pulber ja lahust
They should be taken within one hour after morning and evening meals. 
Neid tuleb võtta ühe tunni jooksul pärast hommiku- ja õhtusööki.
Colorectal cancer 
Kolorektaalvähk
Lonsurf received a marketing authorisation valid throughout the European Union on 25 April 2016. 
Lonsurf on saanud müügiloa, mis kehtib kogu ELis, 25. aprillil 2016.
What measures are being taken to ensure the safe and effective use of Lonsurf? 
Mis meetmed võetakse, et tagada Lonsurfi ohutu ja efektiivne kasutamine?
Other information about Lonsurf 
Muu teave Lonsurfi kohta
The tablets are taken twice a day on certain days of each treatment cycle. 
Tablette võetakse iga ravitsükli teatud päevadel kaks korda ööpäevas.
The European Medicines Agency decided that Lonsurf's benefits are greater than its risks and it can be authorised for use in the EU. 
Euroopa Ravimiamet otsustas, et Lonsurfi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
Lonsurf is available as tablets (15 mg trifluridine and 6.14 mg tipiracil; 20 mg trifluridine and 8.19 mg tipiracil) and is given in treatment cycles of 28 days. 
Lonsurfi turustatakse tablettidena (15 mg trifluridiini ja 6,14 mg tipiratsiili; 20 mg trifluridiini ja 8,19 mg tipiratsiili) ja manustatakse 28-päevaste ravitsüklitena.
All patients had previously received other treatments. 
Kõiki patsiente olid varem ravitud vähemalt kahe muu ravimeetodiga.
What is Lonsurf and what is it used for? 
Mis on Lonsurf ja milleks seda kasutatakse?
As for all medicines, data on the use of Lonsurf are continuously monitored. 
Nagu kõigi ravimite puhul, tehakse Lonsurfi kasutamise kohta pidevat järelevalvet.
Further information on Lonsurf can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lonsurf. 
Lisateave Lonsurfi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/lonsurf Kokkuvõtte viimane uuendus: 09.2019
Why is Lonsurf authorised in the EU? 
Miks Lonsurf ELis heaks kiideti?
This reduces the growth of cancer cells, while normal cells are only slightly affected. 
See vähendab vähirakkude kasvu, kuid normaalsed rakud kahjustuvad vähe.
Tipiracil increases the level of trifluridine in the blood by slowing its breakdown. 
Tipiratsiil suurendab trifluridiini sisaldust veres, aeglustades selle lagunemist.
Lonsurf (trifluridine / tipiracil) 
Lonsurf (trifluridiin/tipiratsiil)
This therefore boosts trifluridine's effect. 
Seega võimendab see trifluridiini toimet.
All patients received supportive care. 
Kõik uuringus osalenud patsiendid said toetavat ravi.
The Agency considered that the measures put in place are adequate to manage these risks. 
Inimravimite komitee tunnistas nende riskide ohjamiseks võetud meetmed asjakohaseks ja piisavaks.
Treatment with Lonsurf should continue for as long as benefits can be seen and the side effects are tolerable. 
Ravi Lonsurfiga tuleb jätkata seni, kuni täheldatakse selle kasulikkust ja kõrvalnähud on talutavad.
Side effects reported with Lonsurf are carefully evaluated and any necessary action taken to protect patients. 
Lonsurfi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
It is used when the cancer is metastatic (has spread to other parts of the body) in patients who have already been treated with, or who cannot be given, other treatments for their cancer. 
Seda kasutatakse, kui vähk on metastaatiline (levinud organismis ka mujale) patsientidel, kes on juba saanud vähiravi muude ravimeetoditega või kellele need ei sobi.
For more information about using Lonsurf, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Lonsurfi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lonsurf have been included in the summary of product characteristics and the package leaflet. 
Lonsurfi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Lonsurf is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells). 
Lonsurf on tsütotoksiline ravim (ravim, mis hävitab jagunevaid rakke, näiteks vähirakke).
Treatment with Lonsurf should be prescribed by a doctor who is experienced in the use of cancer medicines. 
Ravi Lonsurfiga peab määrama vähiravimite kasutamises kogenud arst.
In the body, trifluridine is converted into an active form that is incorporated into DNA, the genetic material of cells. 
Trifluridiin muundub organismis aine aktiivseks vormiks, mis kaasatakse rakkude geneetilisse materjali DNA-sse.
What are the risks associated with Lonsurf? 
Mis riskid Lonsurfiga kaasnevad?
The most common side effects with Lonsurf (which may affect more than 3 in 10 people) are neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), feeling sick, tiredness and anaemia (low red blood cell counts). 
Lonsurfi kõige sagedamad kõrvalnähud (võivad esineda enam kui 3 patsiendil 10st) on neutropeenia (neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus), iiveldus, väsimus ja aneemia (erütrotsüütide ehk vere punaliblede vähesus).
The conversion of trifluridine into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells. 
Trifluridiin muundub aktiivseks vormiks kergemini vähirakkudes kui normaalsetes rakkudes, mistõttu ravimi aktiivse vormi sisaldus on vähirakkudes suurem ja püsib neis kauem.
As a result, trifluridine interferes with DNA function and prevents the cells from dividing to make more cells. 
Selle tulemusena häirib trifluridiin DNA funktsiooni ja takistab rakkude jagunemist ja paljunemist.
Regarding its safety, although Lonsurf's side effects can be serious they are in line with what can be expected for this type of medicine. 
Ehkki ohutuse seisukohalt võivad Lonsurfi kõrvalnähud olla rasked, on need kooskõlas tsütotoksilise ravimi eeldatavate kõrvalnähtudega.
How does Lonsurf work? 
Kuidas Lonsurf toimib?
In a study involving 507 adults with metastatic gastric cancer, patients treated with Lonsurf lived on average for 5.7 months compared with 3.6 months for patients who received placebo. 
Metastaatilise maovähiga 507 täiskasvanu uuringus elasid Lonsurfiga ravitud patsiendid keskmiselt 5,7 kuud ja platseebot saanud patsiendid 3,6 kuud.